本季度信息
荣昌生物披露的2025年报显示，期内营收约为人民币325,000万元，同比增长约89%。经调整净利润（扣除非经常性损益后）由上一财年的亏损人民币150,764.24万元转为盈利约7,850万元，成功扭亏为盈。公司管理层将这一变化归因于两方面重要因素：其一，核心产品泰它西普和维迪西妥单抗在国内市场的销售收入快速提升；其二，对外技术授权交易带来显著收益，同时合作方承担相关研发投入，进一步减轻成本压力。
此外，公司通过优化管理和迭代生产工艺，有效降低产品单位生产成本，毛利率随之提升，销售费用率也显著下降，为整体经营效率改善提供支撑。
业务分项
核心业务方面，泰它西普和维迪西妥单抗在国内市场的销售表现突出，实现快速增长，成为本期收入和利润的重要支撑。公司还与Vor Biopharma Inc达成授权合作，获得除大中华区外该产品的全球开发与商业化权益授权收入。此举不仅增加了公司的技术授权收入，也使部分海外研发费用由合作方承担。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.